(2026). Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis. ClinicoEconomics and Outcomes Research.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Nivolumab-AVD Versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis."
ClinicoEconomics and Outcomes Research 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Nivolumab-AVD Versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis."
ClinicoEconomics and Outcomes Research, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.